HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.

Abstract
The efficacy and safety of azacitidine in elderly patients (aged >65 years) with myelodysplastic syndromes (MDS) treated outside clinical trials are reported. Thirty-eight patients with MDS received azacitidine (75 mg/m(2), schedule 5+2 +2): seven patients were classified as having refractory cytopenia with multilineage dysplasia (RCMD), nine patients with refractory anemia with excess of blasts (RAEB) type 1, 18 patients with RAEB type 2 and four patients with chronic myelomonocytic leukemia type 2 (CMML-2). According to International Working Group (IWG) 2006 criteria, after the first four cycles we detected complete remission in seven patients (CR, 18%), improvement of bone marrow dysplasia and reduction of blast percentage in seven patients (partial response, 18%), stable disease in 20 patients (53%) and progression to acute leukemia in four patients (10%). Median overall survival for all patients treated was 16.4 months. Only mild non-hematologic toxicity was detected (grade 1-2 nausea and pruritus), whereas 55% of patients experienced hematologic side effects (25% grade 3-4 thrombocytopenia and 30% grade 3-4 neutropenia). Our results suggest that advanced age should not preclude effective treatment with azacitidine in non-selected elderly patients wih MDS.
AuthorsMassimo Breccia, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Luigi Petrucci, Marco Mancini, Giuliana Alimena
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 53 Issue 8 Pg. 1558-60 (Aug 2012) ISSN: 1029-2403 [Electronic] England
PMID22280532 (Publication Type: Journal Article)
Chemical References
  • Azacitidine
Topics
  • Aged
  • Aged, 80 and over
  • Anemia, Refractory, with Excess of Blasts (drug therapy)
  • Azacitidine (therapeutic use)
  • Cohort Studies
  • Cytogenetics
  • Disease Progression
  • Female
  • Humans
  • Male
  • Myelodysplastic Syndromes (drug therapy)
  • Remission Induction
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: